Clinical Trial

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-07-13; most recent amendment 2026-07-09.
Trial Details
NCT Number NCT05462106
Lead Sponsor AC Immune SA
Collaborators: Worldwide Clinical Trials
Conditions Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Enrollment 304 participants
Start Date 2022-06-21
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-10